Dear Visitor:

Welcome to our brand new website!
We have overhauled it completely to reflect our sharpened focus as a clinical stage biopharmaceutical company. It is our intention to eventually offer a full range of innovative allergy vaccines based on our exciting peptide-carrier-fusion technology platform covering all major airborne allergens.

The last year was a very exciting period for all of us at Biomay. We have been moving our lead product, the grass pollen allergy vaccine BM32, aggressively from preclinical stage through our first immunotherapy clinical trial. We expect results from this pollen chamber study in the next few months. A birch pollen vaccine (BM31) is currently being readied for development, and we expect a house dust mite product to come on-stream soon. We were very gratified to receive substantial funding from the Centre for Innovation and Technology (ZIT) of the City of Vienna for the development of our ragweed and Japanese cedar program.

We believe that our products will provide allergy patients with much needed treatment options, with an unrivalled efficacy, safety and convenience profile, to provide not only relief of symptoms, but also long term cure.

In addition, we are taking first steps for developing a platform for prophylactic allergy vaccination based on advanced RNA vaccine technology.

We are following a unique business model by combining development of our own pipeline with a contract manufacturing offering to external clients under GMP conditions, which is an important contributor to our revenues. We are gratified that a number of clients have selected us for our unmatched cost and quality profile.

From time to time I plan to provide our view of the science and markets for allergy immunotherapy in this space, and report on our progress. I hope you will share our excitement for the untapped possibilities in our field, which we are poised to exploit.

Best regards

Rainer Henning
Chief Executive Officer